Document Detail

Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
MedLine Citation:
PMID:  16102833     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate cyclosporine 0.1% ophthalmic emulsion over a 1- to 3-year period in moderate to severe dry eye disease patients. DESIGN: Nonrandomized, multicenter, open-label clinical trial extending 2 ophthalmic cyclosporine phase III clinical trials. PARTICIPANTS: Four hundred twelve patients previously dosed for 6 to 12 months with cyclosporine 0.05% or 0.1% in prior phase III trials. INTERVENTION: Patients instilled ophthalmic cyclosporine 0.1% twice daily into both eyes for up to 3 consecutive 12-month extension periods. MAIN OUTCOME MEASURES: Corneal staining, Schirmer tests, and symptom severity assessments were conducted during the first 12-month extension, with a patient survey during the second 12-month extension. Biomicroscopy and visual acuity (VA) examinations, intraocular pressure (IOP) measurements, and adverse effects queries occurred at 6-month intervals. RESULTS: Mean duration of treatment was 19.8 months. Improvements in objective and subjective measures of dry eye disease were modest, probably because of prior treatment with cyclosporine. Most survey respondents said their symptoms began to resolve in the first 3 months of cyclosporine treatment during the previous phase III clinical trials. At study exit, VA decreased in 12.6% (93/738) and increased in 5.4% (40/738) of eyes by > or =2 lines; severity of biomicroscopy findings increased in 3.4% (chemosis; 26/760), 7.2% (conjunctival hyperemia; 55/760), or 8.5% (tear film debris; 64/756) of eyes; and mean IOP increased 0.18 mmHg relative to baseline. The most common treatment-related adverse events were burning (10.9% of patients [45/412]), stinging (3.9% [16/412]), and conjunctival hyperemia (3.4% [14/412]). No serious treatment-related adverse events occurred. Most patients (95.2% [140/147]) said they would continue cyclosporine therapy; 97.9% (143/146) would recommend it to other dry eye patients. CONCLUSIONS: Therapy of chronic dry eye disease with cyclosporine 0.1% ophthalmic emulsion for 1 to 3 years was safe, well tolerated, and not associated with systemic side effects. The results supplement the safety record of the commercially available cyclosporine 0.05% ophthalmic emulsion.
Laurie D Barber; Stephen C Pflugfelder; Joseph Tauber; Gary N Foulks
Related Documents :
7594043 - Immunosuppressive therapy prevents recurrent pericarditis.
25134943 - Does the nephrostomy tract length impact the outcomes of percutaneous nephrolithotomy (...
15313843 - Treatment of refractory status epilepticus with inhalational anesthetic agents isoflura...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Ophthalmology     Volume:  112     ISSN:  1549-4713     ISO Abbreviation:  Ophthalmology     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-03     Completed Date:  2005-10-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1790-4     Citation Subset:  IM    
Department of Ophthalmology, University of Arkansas, Little Rock, Arkansas 72205, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Cyclosporine / administration & dosage*,  adverse effects
Drug Evaluation
Dry Eye Syndromes / drug therapy*,  metabolism,  physiopathology
Immunosuppressive Agents / administration & dosage*,  adverse effects
Intraocular Pressure / physiology
Middle Aged
Ophthalmic Solutions / administration & dosage*,  adverse effects
Tears / metabolism
Treatment Outcome
Visual Acuity / physiology
Reg. No./Substance:
0/Emulsions; 0/Immunosuppressive Agents; 0/Ophthalmic Solutions; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Heterogeneity of MBL-MASP complexes.
Next Document:  Global Rating Assessment of Skills in Intraocular Surgery (GRASIS).